Drug intelligence / Profile preview

plasmalyte

Development stage
Approved
Lead developer
Takeda
Modality
Small Molecules
Administration
Intravenous
01

Overview

Plasmalyte is a family of sterile, nonpyrogenic isotonic crystalloid solutions formulated to closely mimic the electrolyte composition and pH of human plasma. The most common formulations (such as Plasma-Lyte A and Plasma-Lyte 148) contain sodium chloride, potassium chloride, magnesium chloride hexahydrate, sodium acetate trihydrate, and sodium gluconate dissolved in water for injection. These solutions are used intravenously as sources of water and electrolytes for fluid replacement in clinical situations such as burns, trauma (including hemorrhagic shock), surgery (intraoperative fluid replacement), infection with peritoneal irritation or sepsis requiring rapid volume expansion or correction of metabolic acidosis. Plasmalyte provides an alkalinizing effect due to its content of acetate and gluconate anions which are metabolized to bicarbonate. It is compatible with blood products for transfusion purposes[1][2][3][4][5][6].

Brand names
Plasma-LytePlasma-Lyte APlasma-Lyte 148Plasma-Lyte148Plasma-Lyte-148PlasmaLyte APlasmaLyte 148PlasmaLyte148PlasmaLyte-148
Other names
Multiple Electrolytes Injection Type 1 USPbalanced salt solution for infusion

Beyond the preview

Go deeper on plasmalyte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on plasmalyte.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call